Mounjaro Dosage Chart: Strengths, Schedule and Missed Doses
Read the current Mounjaro dosage chart by age, indication, strength, presentation and missed-dose rule in the U.S. and U.K.
Mounjaro Dosage Chart
Current U.S. and U.K. information starts Mounjaro at 2.5 mg once weekly and moves to 5 mg after four weeks; any further increase is in 2.5 mg steps only after at least four weeks on the current dose and only when clinically directed. The adult maximum is 15 mg weekly, while the maximum for patients aged 10 to under 18 treated for type 2 diabetes is 10 mg weekly. A missed dose may be used within four days; after more than four days it is skipped, and two doses must remain at least three days apart. This is a label summary, not a recommendation to increase, restart, split, count pen clicks or extract leftover liquid.
Timeline at a glance
A safe dosage chart needs five columns before any number: country, indication, age group, prescribed presentation and clinician instruction. The same strength can appear in single-dose pens, vials, multi-dose vials or four-dose KwikPens, so milligrams, volume and device technique must never be silently converted.
Match market, indication and age
Current U.S. Mounjaro is for type 2 diabetes from age 10; current U.K. Mounjaro also includes adult weight management. Pediatric weight-management use is not established.
Read initiation as a prescribed phase
Official information uses 2.5 mg weekly for initiation and 5 mg after four weeks. The U.S. label says the initiation strength is not intended for glycaemic control.
Keep every later step clinician-directed
Further 2.5 mg increases require at least four weeks on the current dose. Adult and pediatric ceilings differ, and symptoms or scale change do not select the next step.
Use the four-day rule without doubling
Within four days, current labels say use the missed dose; after more than four days, skip it. Maintain at least three days between doses and never double.
Retrain for the exact device
U.S. labeling includes several presentation types; U.K. patient information describes a four-dose KwikPen. A presentation change requires the new official instructions, not a click-count conversion.
The bars show relative visibility within this guide only. They are not percentages, clinical measurements or personal forecasts.
Why strength, dose, volume and device are separate fields
A milligram strength identifies the prescribed tirzepatide dose, but the supplied presentation may be a single-dose pen, single-dose vial, multi-dose vial or four-dose KwikPen. Volume and technique belong to that exact product's instructions.
The strength sequence is not a performance ladder. Initiation, later increases, maintenance and maximum doses have different roles, and the adult and pediatric ceilings are not interchangeable.
A four-day missed-dose rule covers one missed weekly dose. It does not answer how to restart after a longer interruption or how to manage vomiting, hypoglycaemia, supply changes or a device error.
Deeper visual interpretation
A dosage chart is useful only when it prevents the wrong inference. The current labels share a weekly initiation pattern, but indication, age ceiling, presentation, concentration, volume and device training remain separate fields.
| Role | Adults | Age 10 to under 18 with type 2 diabetes | Boundary |
|---|---|---|---|
| Initiation | 2.5 mg once weekly for 4 weeks | 2.5 mg once weekly for 4 weeks | U.S. label says initiation dose is not intended for glycaemic control |
| Next labeled step | 5 mg once weekly after 4 weeks | 5 mg once weekly after 4 weeks | Every change remains prescribed |
| Further increase | 2.5 mg increments after at least 4 weeks on current dose if needed | 2.5 mg increments after at least 4 weeks on current dose if needed | Symptoms, appetite or scale trend do not choose it |
| Maximum | 15 mg once weekly | 10 mg once weekly | Pediatric weight-management use is not established |
| U.K. maintenance wording | Recommended adult maintenance: 5, 10 or 15 mg | Recommended pediatric diabetes maintenance: 5 or 10 mg | 7.5 and 12.5 mg are available strengths, not listed U.K. maintenance doses |
| Presentation field | Current context | Never infer |
|---|---|---|
| Single-dose pen or vial | U.S. label lists six strengths at 0.5 mL per dose | That another presentation uses the same volume or technique |
| Multi-dose vial | U.S. label lists four doses per vial at 0.6 mL per dose | A home concentration conversion or reusable syringe plan |
| Single-patient KwikPen | U.S. and U.K. information includes four-dose KwikPen presentations | Click counting, partial fixed doses or sharing between people |
| Residual liquid | U.K. product information says excess after the four administered doses is discarded | An extra dose, extraction or combining remnants |
| Changed presentation | Current U.S. label calls for training on the newly supplied presentation | That previous technique transfers automatically |
Use the chart without making a treatment decision
- Write identity first
Country, indication, age, strength, presentation and label revision belong above the chart.
- Locate the prescribed role
Distinguish initiation, current maintenance, one missed dose and a longer interruption.
- Keep time boundaries exact
Four weeks before a later increase, four days for one missed dose and at least three days between doses answer different questions.
- Read the device instructions
Use the current package leaflet and training; do not translate clicks, volume or remnants.
- Escalate uncertainty—not the dose
Contact the prescriber or pharmacist when the product, timing, symptoms or restart plan is unclear.
How to interpret the stages
A recovery timeline combines broad observations from published patient guidance. It cannot know the exact product or device, treatment depth, technique, medical history, skin characteristics or aftercare plan involved in one person’s case.
Use the stages to understand the order in which changes may happen and to prepare questions for a qualified professional. Do not use a general internet timeline to override instructions from the clinician who assessed and treated you.
Aftercare principles
- Record country, indication, age, prescribed strength, presentation, scheduled day and label revision. Do not rely on a screenshot detached from those fields.
- Treat 2.5, 5, 7.5, 10, 12.5 and 15 mg as available strength labels—not a self-selected ladder. Adult recommended maintenance strengths in the U.K. are 5, 10 and 15 mg.
- Keep the pediatric type 2 diabetes maximum of 10 mg separate from the adult maximum of 15 mg. Neither authorizes pediatric weight management.
- Use only the instructions supplied with the exact pen or vial. Do not count clicks, split a fixed dose, combine remnants, transfer liquid or improvise a syringe conversion.
- If insulin or a sulfonylurea is also used, follow the clinician's glucose and hypoglycaemia plan. A dosage chart cannot adjust those medicines.
Contact the prescriber or pharmacist when the presentation differs, more than one dose may have been used, a long interruption has occurred, storage or supply is uncertain, or restarting is being considered. Seek urgent help for severe persistent abdominal pain, serious allergy, breathing difficulty, fainting, severe low glucose or another rapid deterioration. Do not use this page to calculate a restart, compensate for a missed dose, change insulin or use leftover medicine.
Why your timeline may differ
Questions to ask before treatment
- Which country, indication and age group apply?
- What exact presentation and strength were dispensed?
- Is this initiation, maintenance, one missed dose or a longer interruption?
- Are insulin, sulfonylurea, symptoms or a procedure relevant?
- Who will confirm the current prescription and device training?
Mounjaro presentations and licensed indications differ by market even when the strength names look familiar. Use the official leaflet supplied with the exact product; never transfer click counts, concentrations, leftover-liquid practices or device instructions across presentations.
Find official checks for 12 marketsHow this guide was made
5 named sources support the main claims. Each link explains how it was used, with public agencies, professional bodies or primary research preferred.
AI may assist with research organization, drafting and translation, but it is not treated as a source or credential. Read the editorial standards.
Stage bars organize a relative sequence. Original editorial illustrations are conceptual and are not clinical measurements, outcome percentages or personal forecasts.
This version has editorial evidence review, not medical review attributed to a named clinician. It does not replace an individual assessment. Editorial accountability.
Sources
- U.S. Mounjaro Prescribing Information (April 2026)
Current U.S. indication, adult and pediatric schedule, maxima, missed-dose rule, presentations, strengths, training and safety instructions.
- DailyMed: U.S. Mounjaro Drug Information
Official structured U.S. label and presentation context for cross-checking the current supplied product.
- UK eMC: Mounjaro Summary of Product Characteristics (April 2026)
Current U.K. adult and pediatric posology, weight-management context, maintenance strengths, missed-dose and special-population wording.
- UK eMC: Mounjaro KwikPen Patient Information Leaflet
Four-dose KwikPen, weekly schedule, prescribed escalation, missed-dose boundary, device use and safety wording for patients.
- FDA: Concerns with Unapproved GLP-1 Drugs
Unapproved, compounded, fraudulent and counterfeit supply, concentration, dosing-error and storage risks.
Frequently asked questions
What should I know about Mounjaro Dosage Chart?
Current U.S. and U.K. information starts Mounjaro at 2.5 mg once weekly and moves to 5 mg after four weeks; any further increase is in 2.5 mg steps only after at least four weeks on the current dose and only when clinically directed. The adult maximum is 15 mg weekly, while the maximum for patients aged 10 to under 18 treated for type 2 diabetes is 10 mg weekly. A missed dose may be used within four days; after more than four days it is skipped, and two doses must remain at least three days apart. This is a label summary, not a recommendation to increase, restart, split, count pen clicks or extract leftover liquid.
Why can the timeline differ from person to person?
Treatment type, depth, technique, anatomy, skin and tissue response, health history, medication, aftercare and complications can all change timing. The treating professional’s instructions take priority over a general guide.
When should I contact a professional?
Contact the prescriber or pharmacist when the presentation differs, more than one dose may have been used, a long interruption has occurred, storage or supply is uncertain, or restarting is being considered. Seek urgent help for severe persistent abdominal pain, serious allergy, breathing difficulty, fainting, severe low glucose or another rapid deterioration. Do not use this page to calculate a restart, compensate for a missed dose, change insulin or use leftover medicine.
Keep dosage, outcomes and symptoms in separate records
Use the clinical results timeline for group evidence and the side-effects guide for symptom action boundaries. Neither page modifies the exact prescription summarized here.
Read the Mounjaro results timeline Read the Mounjaro side-effects guide Open the private 3D plannerExplore the complete GLP-1 beauty and body guide
Move between product identity, side-effect timing, facial documentation, hair-loss evidence, exercise safety and private tools without turning appearance into a diagnosis or prescription decision.
Open the GLP-1 topic hub Read the GLP-1 side-effects timelineRelated beauty guides
View BodyLiposuction Recovery Timeline: Week 1 to Month 6
A visual guide to bruising, swelling, activity limits and when body-contour results become easier to see after liposuction.
Read next BODYNonsurgical Body Contouring: Recovery and Results Timeline
Compare fat freezing, heat, ultrasound and magnetic body-contouring timelines, side effects, results and device-specific risks.
Read next BODYMounjaro Face: Facial Volume Changes, Evidence and Options
What ‘Mounjaro face’ means, why facial volume may change with substantial weight loss, what evidence can and cannot prove, and how to plan a qualified review.
Read nextThis guide is for general education only. It is not medical advice, diagnosis, a treatment recommendation or a prediction of individual results. BeautiNext is not a clinic. Seek care from an appropriately qualified professional.